Tag:

Johnson & Johnson

Latest Headlines

Latest Headlines

WSJ: FBI probes J&J over morcellator safety risks

How much did Johnson & Johnson know about the risks of power morcellators--now suspended on safety concerns--before it pulled them from the market last year? That's the subject of a new investigation, headed up by the FBI's Newark, NJ, office,  The Wall Street Journal 's sources say.

J&J sets up innovation hub inside Karolinska Institutet

Johnson & Johnson has established an outpost within Karolinska Institutet. The arrangement sees J&J set an innovation hub at the Swedish medical university, from which it will keep tabs on academic research breakthroughs and support the advance of such ideas into life science startups.

WSJ: J&J faces FBI probe over power morcellator devices

Johnson & Johnson is facing more backlash over power morcellator devices used in minimally invasive gynecological procedures, as the FBI investigates how much the company knew about the products' risks before pulling them from the market last year.

FDA approves long-acting formulation of J&J schizophrenia med

The FDA gave the green light to Johnson & Johnson's Invega Trinza, which is injected four times a year, making it the longest-acting schizophrenia drug on the market.

J&J picks up where Novo left off with an autoimmune licensing deal

Novo Nordisk, gradually exiting the world of autoimmune R&D, has found a home for one of its former projects, handing a development program over to Johnson & Johnson for an undisclosed sum.

J&J promises new uses for old meds to keep pharma sales flying high

Johnson & Johnson is riding high on strong sales for standout meds, but some slowdown could be on the horizon as competition increases for its top-selling drugs. And J&J is not going down without a fight, planning to roll out new versions of old meds to keep its pharma numbers in tip-top shape.

J&J touts a blockbuster-rich pipeline with 10 filings on the horizon

Johnson & Johnson says it's on track to submit more than 10 new drugs for FDA approval over the next four years, and the company believes each of those contenders has the potential to bring in $1 billion in peak revenue.

Medivation's Xtandi sales fell short in Q1, but analysts say it's gaining on J&J's Zytiga

Astellas and Medivation may have disappointed analysts with their first-quarter Xtandi sales. But recent script numbers suggest the disappointment may be short-lived--and that the prostate cancer pill may be gaining ground on its head-to-head rival, Johnson & Johnson's Zytiga.

J&J buys into Achillion's hep C pipeline for up to $1.1B

Johnson & Johnson, fighting to keep up with the blockbuster race to launch quick cures for hepatitis C, has agreed to pay as much as $1.1 billion for the rights to Achillion Pharmaceuticals' pipeline of antiviral treatments.

J&J sees Invega franchise boost with FDA nod for longer-acting Trinza version

Johnson & Johnson's once-a-month antipsychotic med Invega Sustenna is already raking in blockbuster numbers, but the company is eyeing even bigger sales for its franchise with FDA approval for a longer acting formula.